Search Results

Complete Genomics, a pioneering genomic sequencing company, announced the May 22 opening of its Customer Experience Center demonstration lab near Boston’s biotech hub.

Complete Genomics, a pioneering genomic sequencing company, recently welcomed vendors, suppliers, customers and employees to a May 17 grand opening celebration of its 10,115 square foot manufacturing facility at its headquarters in San Jose, California.

Complete Genomics and seqWell announced a partnership aimed at expanding the range of library preparation product offerings available to Complete Genomics customers.

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it has completed its acquisition of C2i Genomics, Inc., adding whole-genome minimal residual disease (MRD) capabilities to its novel diagnostics platform.

Complete Genomics announced a joint marketing agreement with Gencove, a pioneer of low-pass whole genome sequencing imputation and analysis, to offer a bundled solution to deliver high-capacity and cost-effective whole genome information.

Complete Genomics, Inc. announced its partnership with Integrated DNA Technologies, a global genomics solutions provider, to develop an ecosystem of advanced compatible products based on Complete Genomics’ innovative DNBSEQ™ sequencing platforms.

Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”) and ThreeD Capital Inc. (CSE: IDK) (OTCQB: IDKFF) (“ThreeD”), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, are pleased to announce the completion of its previously announced Securities Purchase Agreement (the “Agreement”).

Sanofi announced the completion of its acquisition of Inhibrx, Inc. The acquisition adds SAR447537 to Sanofi’s rare disease pipeline, underscoring the company’s commitment to pursuing differentiated and potential best-in-class medicines that build upon our existing strengths and capabilities..